hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06364514 id: IRB-P00047313 briefTitle: PICNIC Study - PatIent Centered aNtIbiotic Courses in Children With Medical Complexity overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2025-07-01 date: 2025-10-01 date: 2024-04-15 date: 2024-04-15 name: Boston Children's Hospital class: OTHER briefSummary: To determine if clinicians can safely reduce antibiotic exposure in children with medical complexity (CMC) who are diagnosed with pneumonia by implementing an intervention that bases total antibiotic duration on an individual's clinical stability. conditions: Pneumonia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: Clinical Stability Assessment measure: Proportion of eligible patients who consent to participate in the intervention measure: Rate of persistent and worsening respiratory symptoms measured by patient's clinical status; the rate of emergency department revisit or hospital readmission within 1 week of antibiotic discontinuation measure: Median days of antibiotics received for patients in the intervention group as well as from historical control group sex: ALL minimumAge: 2 Years maximumAge: 25 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06364501 id: KH801 briefTitle: Phase 1 Trial of KH801 overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-05-01 date: 2030-05-01 date: 2024-04-15 date: 2024-04-17 name: Beijing Kanghong Biopharmaceutical Co., Ltd. class: INDUSTRY briefSummary: KH801 is a injection used for advanced solid tumors which must be diluted with 5% Dextrose Or 0.9% sodium chloride Injection.
This study is expected to include a total of approximately 17-42 participants. conditions: Advanced Solid Tumors studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 17 type: ESTIMATED name: KH801 measure: MTD measure: DLT measure: RP2D measure: AE measure: Cmax measure: Tmax measure: T1/2 measure: AUC0-t measure: CL measure: AUC0-inf measure: anti-drug antibody (ADA) measure: Objective Response Rate（ORR） measure: Disease Control Rate (DCR) measure: Duration of Response (DOR) measure: Median Progression-Free Survival (mPFS) measure: Overall Survival（OS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Peking University Cancer Hospital city: Peking state: Beijing country: China name: Lin Shen role: CONTACT name: Lin Shen role: PRINCIPAL_INVESTIGATOR lat: 39.9075 lon: 116.39723 facility: Sun Yat-sen Memorial Hospital,Sun Yat-sen University city: Guangzhou state: Guangdong country: China name: ErWei Song role: CONTACT phone: 18982182468 email: 022516@cnkh.com name: ErWei Song role: PRINCIPAL_INVESTIGATOR name: Junyan Wu role: PRINCIPAL_INVESTIGATOR name: Herui Yao role: PRINCIPAL_INVESTIGATOR lat: 23.11667 lon: 113.25 facility: Central Hospital Affiliated To Shandong First Medical University city: Jinan state: Shandong country: China name: Meili Sun role: CONTACT name: Meili Sun role: PRINCIPAL_INVESTIGATOR lat: 36.66833 lon: 116.99722 facility: West China Second University Hospital,Sichuan University/West China Women's and Children's Hospital city: Chengdu state: Sichuan zip: 610000 country: China name: Rutie Yin role: CONTACT name: Rutie Yin role: PRINCIPAL_INVESTIGATOR lat: 30.66667 lon: 104.06667 hasResults: False
nctId: NCT06364488 id: 295721 briefTitle: TrueBlue Clinical Study - Investigating the Use of a Mobile Phone App TrueBlue for Monitoring Depression and Anxiety overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-10-31 date: 2025-07-31 date: 2024-04-15 date: 2024-04-15 name: BlueSkeye AI class: INDUSTRY name: Institute of Mental Health Nottingham name: Nottinghamshire Healthcare NHS Trust name: Nottingham University Hospitals NHS Trust briefSummary: This trial will assess the safety, feasibility, acceptability, usability and agreement with validated scales of an automated mood monitoring App (TrueBlue), in adult, perinatal participants (recruited between 12 weeks of pregnancy and 12 weeks post-partum), recruited across multiple sites in Nottinghamshire, United Kingdom (UK). An initial within-study pilot phase will assess key aspects of the study including recruitment rate, usability issues and a detailed understanding of any device related adverse events; prior to full recruitment of a total 125 participants over a total 14-month period. conditions: Depression conditions: Depression, Postpartum conditions: Anxiety in Pregnancy conditions: Anxiety conditions: Anhedonia conditions: Perinatal Depression studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: 125 participants, of whom 12 will enter the initial 5-month within-study pilot phase aimed at understanding any device-related adverse events and usability issues. primaryPurpose: OTHER masking: NONE count: 125 type: ESTIMATED name: TrueBlue App measure: The rate of device related adverse events measure: Rate of initial use (assessing feasibility and acceptability) measure: Rate of New Depression or Risk (Suicidality) events measure: Rate of referral to Perinatal Psychiatry services measure: Rate of acceptance of referrals to Perinatal Psychiatry measure: Diagnosis rate for depression, or other mental health problems, during the period of study. measure: Continued use (acceptability) measure: Loss to follow-up measure: Usability (quantitative measure) measure: Agreement between TrueBlue generated score and validated scales measure: Thematic results sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Nottingham University Hospitals NHS Trust city: Nottingham state: Nottinghamshire zip: NG7 2UH country: United Kingdom name: Nia Jones role: CONTACT email: Nia.Jones@nottingham.ac.uk role: CONTACT email: TrueBlue@nottingham.ac.uk name: Nia Jones role: PRINCIPAL_INVESTIGATOR lat: 52.9536 lon: -1.15047 facility: Nottinghamshire Healthcare NHS Foundation Trust city: Nottingham zip: NG3 6AA country: United Kingdom name: Bonnie MILLAR role: CONTACT email: bonnie.millar@nottingham.ac.uk role: CONTACT email: TrueBlue@nottingham.ac.uk name: Neil Nixon, MBBS, DM role: PRINCIPAL_INVESTIGATOR name: Deepa Bagepalli Krishnan role: SUB_INVESTIGATOR name: Zaib un Nisa role: SUB_INVESTIGATOR name: Amy Au-Yong role: SUB_INVESTIGATOR name: Christina Kelly role: SUB_INVESTIGATOR lat: 52.9536 lon: -1.15047 hasResults: False
nctId: NCT06364475 id: BezmialemVU-TF-AÖ-1 briefTitle: Could a Time-restricted Diet Compete With a Calorie-restricted 6-meal Diet? overallStatus: COMPLETED date: 2021-11-01 date: 2022-07-01 date: 2022-09-01 date: 2024-04-15 date: 2024-04-15 name: Bezmialem Vakif University class: OTHER briefSummary: The prevalence of obesity and obesity-related diseases are on the rise worldwide. The widely accepted approach in dietary treatment of obesity is the calorie-restricted three meals-three snacks a day diet; however, alternative approaches are needed. This study was conceived with a view to comparing time-restricted eating, a method which can be easily conveyed and applied in overcoming obesity, to a six meals a day diet. 174 participants aged between 18-65 with a BMI\>25 kg/m2 were included. Diet lists with similar calorie, macro counts suitable for their respective group were prepared. Anthropometric measurements, blood pressure, blood tests were analyzed before the study and at the end of the 8-week. conditions: Overweight and Obesity studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: One group 16:8 time-restricted intermittent fasting and the other group energy-restricted six-meal eating. Both of groups with an eating plan suitable with their groups and 400 kcal lower than the total daily energy requirement and with similar macronutrient content (50% carbohydrates, 25% fat and 25% protein). primaryPurpose: PREVENTION masking: NONE count: 137 type: ACTUAL name: 16:8 Time-Restricted Intermittent Fasting Group name: Energy-Restricted Six-Meal Group measure: Weight measured in kilogram measure: Body composition measure: Body mass index measure: Waist-to-height ratio (WHtR) measure: Waist circumference in centimetres sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: İstanbul Sabri Artam Vakfi Family Medicine Center city: İ̇stanbul zip: 34473 country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06364462 id: ZLRK202301 briefTitle: Precise Evaluation Criteria for Histological Regression of NASH Fibrosis overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-03-09 date: 2027-04-01 date: 2024-04-15 date: 2024-04-15 name: Beijing Friendship Hospital class: OTHER briefSummary: It is an observational study of NASH patients with a calculated sample size of 220. Liver biopsy-proven NASH fibrosis with stage F2-F4 will be recruited in this study. A second biopsy will be performed after clinical trials or 1-3 years of lifestyle intervention. Patients will be followed up at baseline and every six months with h-CRP, liver function tests, fasting blood glucose, fasting insulin, ferritin, liver ultrasonography, and liver stiffness measurements. conditions: NASH conditions: Liver Fibrosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 220 type: ESTIMATED name: lifestyle intervention measure: Regression of NASH fibrosis measure: Dynamic changes of liver stiffness measurements (LSM) measure: Dynamic changes of CAP measure: Dynamic changes of MRE measure: Dynamic changes of MRI-PDFF measure: Dynamic changes of non-invasive liver fibrosis models measure: Dynamic changes of non-invasive liver fibrosis models measure: Dynamic changes of non-invasive liver fibrosis models measure: Dynamic changes of non-invasive liver fibrosis models measure: Dynamic changes of non-invasive liver fibrosis models measure: Dynamic changes of metabolic markers measure: Dynamic changes of metabolic markers measure: Dynamic changes of metabolic markers measure: Incidence of liver-related events measure: Incidence of extrahepatic related events sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06364449 id: 202309052RIND briefTitle: Clinical Decision Tree Analysis of Hemodialysis Arteriovenous Access Choices and Creations - a Multiple-center Retrospective Cohort Study overallStatus: RECRUITING date: 2023-10-13 date: 2024-05-07 date: 2024-05-31 date: 2024-04-15 date: 2024-04-15 name: National Taiwan University Hospital class: OTHER briefSummary: Our study aim was to utilize a decision tree analysis (DTA) model to gain insight into the decision-making process within a multiple-center cohort. conditions: Decision Tree Analysis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 600 type: ESTIMATED name: No intervention measure: predicted AV access choices measure: to determine factors affecting clinical use of the targeted AV access over a variable timeframe sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Taiwan University Hospital status: RECRUITING city: Taipei country: Taiwan name: Chih-Yang Chan, MD Phd role: CONTACT lat: 25.04776 lon: 121.53185 hasResults: False
nctId: NCT06364436 id: AksarayU1 briefTitle: Distant Reiki Therapy on Postpartum Period Fatigue and Depression overallStatus: ACTIVE_NOT_RECRUITING date: 2022-06-03 date: 2024-03-18 date: 2024-04-10 date: 2024-04-15 date: 2024-04-15 name: Aksaray University class: OTHER briefSummary: This research was conducted to evaluate the effect of Reiki therapy applied to women in the postpartum period on the risk of fatigue and postpartum depression. conditions: PostPartum Depression studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 85 type: ESTIMATED name: Reiki energy therapy measure: Visual Analog Scale for Fatigue (VAS-F) measure: Edinburgh Postnatal Depression Scale (EPDS) sex: FEMALE minimumAge: 18 Years maximumAge: 49 Years stdAges: ADULT facility: Aksaray University city: Aksaray state: Merkez country: Turkey lat: 38.37255 lon: 34.02537 hasResults: False
nctId: NCT06364423 id: 10001599 id: 001599-C briefTitle: Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2029-07-01 date: 2030-07-01 date: 2024-04-15 date: 2024-04-26 name: National Cancer Institute (NCI) class: NIH briefSummary: Background:
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are blood cancers that affect certain white blood cells. Advanced forms of these diseases are difficult to treat. CD19 is a protein often found on the surfaces of these cancer cells. Researchers can modify a person's own immune cells (T cells) to target CD19. When these modified T cells are returned to the body-a treatment called anti-CD19 chimeric antigen receptor (CAR) T cell therapy-they may help kill cancer cells.
Follow-up visits will continue for 5 years. conditions: B-Cell Chronic Lymphocytic Leukemia conditions: Leukemia, Lymphocytic, Chronic, B-Cell conditions: B-Lymphocytic Leukemia, Chronic studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 66 type: ESTIMATED name: Autologous HuCD19 ( Anti-CD19)CAR T cells name: Cyclophosphamide name: Fludarabine name: Rituximab measure: Phase I: Determine the safety of administering T-cells expressing a fully-human anti-CD19 CAR to participants with advanced CLL or SLL. measure: Phase II: Determine the overall response rate (ORR) of T cells expressing an anti-CD19 CAR with a fully-human single chain variable fragment (scFv) to participants with advanced CLL measure: Phase I: Assess overall response rate measure: Phase I+II: Assess complete response rate measure: Phase I+II: Assess duration of responses measure: Phase I+II: Determine the ORR for re treatment with rituximab, chemotherapy and CAR T cells in eligible patients measure: Phase II: Determine the frequency of grade 3-4 adverse events at the Optimal Dose sex: ALL minimumAge: 18 Years maximumAge: 120 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Institutes of Health Clinical Center city: Bethesda state: Maryland zip: 20892 country: United States name: NCI Medical Oncology Referral Office role: CONTACT phone: 240-760-6050 email: ncimo_referrals@nih.gov name: Micaela Ganaden, M.D. role: CONTACT phone: (240) 858-3654 email: ncicar@mail.nih.gov lat: 38.98067 lon: -77.10026 hasResults: False
nctId: NCT06364397 id: ESPRIT202403 briefTitle: Efficacy of ERCP in the Diagnosis and Treatment of Idiopathic Recurrent Acute Pancreatitis acronym: ESPRIT overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-03 date: 2026-05 date: 2024-04-15 date: 2024-04-18 name: Changhai Hospital class: OTHER name: Peking Union Medical College Hospital name: First People's Hospital of Hangzhou briefSummary: The goal of this clinical trial is to learn if endoscopic retrograde cholangiopancreatography (ERCP) works to treat idiopathic recurrent pancreatitis (IRAP) in adults. It also clarify the efficacy of ERCP in the diagnosis of IRAP. The main questions it aims to answer are:
Participants will be randomly allocated to receive ERCP (pancreatic sphincterotomy and pancreatic stent placement) or conservative treatment and be followed for 1 year. conditions: Recurrent Acute Pancreatitis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 158 type: ESTIMATED name: ERCP name: Health education and conservative management of clinical routines measure: Recurrence rate of AP measure: Ratio of reduced AP episodes measure: Proportion of patients with reduced AP episodes measure: Severity of AP measure: Evaluation of quality of life measure: Evaluation of psychological condition measure: Proportion of patients diagnosed by ERCP. sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Changhai Hospital city: Shanghai state: Shanghai zip: 200433 country: China lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06364384 id: E2024074 briefTitle: Radical Synchronous Chemoradiotherapy With DDP/5-FU and PD-1 for Non-metastatic Rectal Squamous Cell Carcinoma overallStatus: RECRUITING date: 2024-04-20 date: 2024-04-20 date: 2027-02-28 date: 2024-04-15 date: 2024-04-15 name: Sixth Affiliated Hospital, Sun Yat-sen University class: OTHER briefSummary: The goal of this clinical trial is to learn if PD-1 monoclonal antibody combined with radical chemoradiotherapy works to treat rectal squamous cell carcinoma (rSCC). lt will also learn about the safety of the regime. The main questions it aims to answer are:
Participants will receive chemotherapy with DDP and 5-FU, immunotherapy with PD-1 monoclonal antibody and radiotherapy with a total dose of 50-54GY. conditions: Rectal Squamous Cell Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: PD-1 and CRT measure: 1-year tumor-free survival(DFS) measure: 1-year overall survival (OS) measure: 1-year relapse-free survival (RFS) measure: 1-year metastasis free survival (DMFS) measure: Incidence of chemotherapy and immunotherapy-related adverse reactions measure: Complete response rate (CRR) measure: 1-year stoma-free survival sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sixth Affiliated Hospital, Sun Yat-sen University status: RECRUITING city: Guangzhou state: Guangdong country: China name: Jun Huang, MD role: CONTACT phone: +86-13926451242 email: huangj97@mail.sysu.edu.cn lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06364371 id: E2023210 briefTitle: Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer overallStatus: RECRUITING date: 2024-05-01 date: 2025-06-01 date: 2026-06-01 date: 2024-04-15 date: 2024-04-15 name: Sixth Affiliated Hospital, Sun Yat-sen University class: OTHER briefSummary: The goal of this observational study is to establish a dynamic multi-omics integration model for predicting pathological complete response (pCR) after neoadjuvant treatment in locally advanced (T3-4NxM0) rectal cancer, providing support for subsequent patient selection for the watch-and-wait strategy. The main question it aims to answer is:
What is the predictive value of this model to assess individual achievement of pathological complete response (pCR) after neoadjuvant treatment? Eligible patients will be prospectively enrolled, and the clinical features of their pre-neoadjuvant treatment, during-treatment, and post-treatment preoperative will be collected and annotated. conditions: Predictive Cancer Model conditions: Pathologic Complete Response studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 106 type: ESTIMATED name: Medical examination measure: Area under curve(AUC) measure: Sensitivity measure: Specificity measure: Negative predictive value(NPV) measure: Positive predictive value(PPV) sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Sixth Affiliated Hospital, Sun Yatsen University status: RECRUITING city: Guangzhou state: Guangdong country: China name: Jun Huang role: CONTACT phone: 13926451242 email: huangj97@mail.sysu.edu.cn lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06364358 id: IRB23-0385 id: 5R21DK121262 type: NIH link: https://reporter.nih.gov/quickSearch/5R21DK121262 briefTitle: Interactive Computer-adaptive Chronic Kidney Disease Education Program acronym: ICCKD overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-12 date: 2025-04 date: 2024-04-15 date: 2024-04-15 name: University of Chicago class: OTHER name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) briefSummary: The goal of this pilot clinical trial is to evaluate a culturally tailored computerized education program in hospitalized African-American patients with advanced chronic kidney disease (CKD). The main question it aims to answer are: does computerized adaptive education (CAE) increase patients' knowledge about CKD self-care and renal replacement therapy (RRT) options compared to usual care (UC) and will CAE will be increase patients' intent to participate in CKD self-care and RRT preparation compared to UC conditions: Chronic Kidney Diseases conditions: Hypertension studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 120 type: ESTIMATED name: Computerized CKD Education name: Usual Hospital Care measure: Change in CKD Knowledge baseline to post patient education intervention measure: Change in Knowledge about end stage kidney disease (ESKD) treatments from baseline to 1 day post patient education intervention measure: Change in ESKD Treatment Preferences from baseline to 1 day post-intervention measure: Change in Patient Activation Measure from Baseline to 30 days Post-intervention measure: Increase in Health Intent baseline to post intervention (at 1 day and 30 day follow-up) measure: CKD Self-Management from baseline to 30 day post-intervention sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Chicago Medical Center city: Chicago state: Illinois zip: 60637 country: United States lat: 41.85003 lon: -87.65005 hasResults: False
nctId: NCT06364332 id: ChatsafeNL id: 2023.0348 type: OTHER domain: Medical Ethics Committee VUmc briefTitle: #Chatsafe Netherlands: a Social Media Intervention to Improve Dutch Young People's Safe Communication About Suicide Online acronym: CSNL overallStatus: NOT_YET_RECRUITING date: 2024-04-04 date: 2024-12 date: 2025-03 date: 2024-04-15 date: 2024-04-15 name: 113 Suicide Prevention class: OTHER name: Orygen name: Mind briefSummary: Suicide is the leading cause of death among young people (YP) aged 10 to 25 years in the Netherlands. In addition, YP report high rates of suicidal ideation (16%). While suicidal behavior is a complex phenomenon with many factors and causes, the role of social media is becoming more prominent, especially for YP. Social media has been shown to be a source where YP can find support, but it's also a place where suicidal behavior is glorified or normalized, which can be triggering or harmful to other social media consumers.
The #Chatsafe guidelines were developed by Orygen Australia to better equip young people to communicate safely about suicide on social media. These guidelines are supported by a social media campaign to make the content of the guidelines more accessible to them. The #Chatsafe intervention consists of both the guidelines and the social media campaign. A small-scale Australian feasibility study showed promising results in terms of the acceptance and safety of the campaign, and safety regarding communicating about suicide on social media platforms. Currently, in Australia it is tested to what extent these results hold up in a Randomized Controlled Trial (RCT) (Robinson et al., 2023).